Merck's new oral antidiabetic agent joins domestic type 2 diabetes market
The Korea Food and Drug Administration (KFDA) has recently approved sitagliptin phosphate (Januvia), an oral diabetes medication in a new class of drugs known as DPP-4 inhibitors.
Taken as a once-...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
